Research graph
References from A rapid sporozoite viability assay identifies leads and targetable enzymatic activities against the zoonotic Cryptosporidium parvum. Local targets link to admitted publications; unresolved targets remain external evidence.
High-throughput cell viability assessment using a luminescent ATP detection assay
10.1016/bs.mcb.2025.03.015 · 2026 · External reference
Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions
10.1128/aac.40.11.2468 · 1996 · External reference
Cryptosporidium oocyst purification using discontinuous gradient centrifugation
10.1007/978-1-0716-4824-7_22 · 2026 · External reference
Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients
10.1111/j.1550-7408.1996.tb05015.x · 1996 · External reference
Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth
10.1128/aac.02460-12 · 2013 · External reference
Biological functions of kojic acid and its derivatives in medicine, cosmetics, and food industry: insights into health aspects
10.1002/ardp.202200215 · 2022 · External reference
Genomic heterogeneity of NAD(P)H dehydrogenase predisposes Cryptosporidium to clofazimine resistance
10.1038/s41564-026-02331-5 · 2026 · External reference
Final report of the safety assessment of kojic acid as used in cosmetics
10.1177/1091581810385956 · 2010 · External reference
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium
10.1016/s1473-3099(14)70772-8 · 2015 · External reference
Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by beta-lactamase from Mycobacterium tuberculosis
10.1021/bi400177y · 2013 · External reference
Current advances in developing new antimicrobial agents against non-tuberculous Mycobacterium
10.3390/antibiotics14121189 · 2025 · External reference
Insights of antiparasitic activity of sodium diethyldithiocarbamate against different strains of Trypanosoma cruzi
10.1038/s41598-021-90719-0 · 2021 · External reference
A review of the importance of cryptosporidiosis in farm animals
10.1016/s0020-7519(99)00076-4 · 1999 · External reference
Human metallo-beta-lactamase enzymes degrade penicillin
10.1038/s41598-019-48723-y · 2019 · External reference
Colloidal aggregation confounds cell-based Covid-19 antiviral screens
10.1021/acs.jmedchem.4c00597 · 2024 · External reference
The five-parameter logistic: a characterization and comparison with the four-parameter logistic
10.1016/j.ab.2005.04.035 · 2005 · External reference
Luminescence-based, Low- and medium-throughput assays for drug screening in Schistosoma mansoni larval stage
10.1007/978-1-0716-0635-3_18 · 2020 · External reference
The existing drug vorinostat as a new lead against cryptosporidiosis by targeting the parasite histone deacetylases
10.1093/infdis/jix689 · 2018 · External reference
Cryptosporidiosis: from prevention to treatment, a narrative review
10.3390/microorganisms10122456 · 2022 · External reference
Pyrrolopyrimidine bumped kinase inhibitors for the treatment of cryptosporidiosis
10.1021/acsinfecdis.0c00803 · 2021 · External reference
HTS assay validation
2012 · External reference
A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio
10.1177/1087057105285610 · 2006 · External reference
Discovery of novel anti-cryptosporidial activities from natural products by in vitro high-throughput phenotypic screening
10.3389/fmicb.2019.01999 · 2019 · External reference
A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors
10.1038/s41467-019-09880-w · 2019 · External reference
Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: a comprehensive review
10.3389/fcimb.2023.1115522 · 2023 · External reference
DrugBank 6.0: the DrugBank knowledgebase for 2024
10.1093/nar/gkad976 · 2024 · External reference
In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain
10.1093/jac/dkh080 · 2004 · External reference
Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the global enteric multicenter study, GEMS): a prospective, case-control study
10.1016/s0140-6736(13)60844-2 · 2013 · External reference
Revisiting the resazurin-based sensing of cellular viability: widening the application horizon
10.3390/bios12040196 · 2022 · External reference
10.1371/journal.ppat.1012881 · 2025 · Admitted local publication
The mucin-like, secretory type-I transmembrane glycoprotein GP900 in the apicomplexan Cryptosporidium parvum is cleaved in the secretory pathway and likely plays a lubrication role
10.1186/s13071-022-05286-8 · 2022 · External reference
Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation
10.1016/j.ejmech.2018.04.006 · 2018 · External reference
A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis
10.1371/journal.pntd.0005373 · 2017 · External reference
Cryptosporidiosis drug discovery: opportunities and challenges
10.1021/acsinfecdis.6b00094 · 2016 · External reference
Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis
10.1038/s41564-024-01810-x · 2024 · External reference
A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis
10.1038/nature22337 · 2017 · External reference
Drug design of tyrosinase inhibitors
10.1016/bs.enz.2024.06.001 · 2024 · External reference
Update on Cryptosporidium and Giardia infections in cattle
10.1016/j.pt.2004.01.015 · 2004 · External reference
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in Non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
10.3324/haematol.2016.154377 · 2017 · External reference
An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotes
10.1016/j.ijpara.2008.11.012 · 2009 · External reference
Study of the economic impact of cryptosporidiosis in calves after implementing good practices to manage the disease on dairy farms in Belgium, France, and the Netherlands
2023 · External reference
Cryptosporidium and Giardia: treatment options and prospects for new drugs
10.1016/j.exppara.2009.07.005 · 2010 · External reference
Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide
10.1086/321008 · 2001 · External reference
Taxonomy and molecular epidemiology of Cryptosporidium and Giardia - a 50 year perspective (1971-2021)
10.1016/j.ijpara.2021.08.007 · 2021 · External reference
Determining the protein repertoire of Cryptosporidium parvum sporozoites
10.1002/pmic.200700804 · 2008 · External reference
Long-term production effects of clinical cryptosporidiosis in neonatal calves
10.1016/j.ijpara.2020.03.002 · 2020 · External reference
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma
10.7243/2049-7962-2-21 · 2013 · External reference
Design of signal windows in high throughput screening assays for drug discovery
10.1177/108705719700200306 · 1997 · External reference
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against acetaminophen hepatotoxicity in mice
10.1016/s0168-8278(02)00384-7 · 2003 · External reference
Development of a phase 1 cryptosporidiosis controlled human challenge model in healthy volunteers using current good manufacturing practice Cryptosporidium Parvum oocysts and conducted under an investigational new drug application
10.1093/infdis/jiag246 · 2026 · External reference
Antiplasmodial activity of Vachellia xanthophloea (Benth.) P.J.H. hurter (African fever tree) and its constituents
10.3390/ph15040470 · 2022 · External reference
Life cycle progression and sexual development of the apicomplexan parasite Cryptosporidium parvum
10.1038/s41564-019-0539-x · 2019 · External reference
Dynamics of gut mucosal and systemic Th1/Th2 cytokine responses in interferon-gamma and interleukin-12p40 knock out mice during primary and challenge Cryptosporidium parvum infection
10.1016/j.imbio.2008.11.015 · 2009 · External reference
Efficacy of halofuginone lactate in the prevention of cryptosporidiosis in dairy calves
10.1136/vr.d1492 · 2011 · External reference
Quantitative and qualitative comparisons of cryptosporidium faecal purification procedures for the isolation of oocysts suitable for proteomic analysis
10.1016/j.ijpara.2006.02.023 · 2006 · External reference
Interactions of CB1 and mGlu5 receptor antagonists in food intake, anxiety and memory models in rats
10.1016/j.pbb.2012.09.016 · 2012 · External reference
SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5
10.1016/s0022-3565(24)34881-5 · 1999 · External reference
Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum
10.1038/nature14651 · 2015 · External reference
Phenotypic high-throughput screening and drug efficacy test against the growth of Cryptosporidium parvum in vitro by qRT-PCR
10.1007/978-1-0716-4824-7_18 · 2026 · External reference
Requirement of microtubules for secretion of a micronemal protein CpTSP4 in the invasive stage of the apicomplexan Cryptosporidium parvum
10.1128/mbio.03158-23 · 2024 · External reference
A comprehensive proteome and the first phosphoproteome reveal extensive phosphorylation of carbohydrate metabolism in Cryptosporidium parvum sporozoites
10.1186/s13071-026-07538-3 · 2026 · External reference
New beta-lactam-beta-lactamase inhibitor combinations
10.1128/cmr.00115-20 · 2020 · External reference
Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani
2019 · External reference
Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro
10.3389/fmicb.2015.00991 · 2015 · External reference
High-throughput screening of drugs against the growth of Cryptosporidium parvum in vitro by qRT-PCR
10.1007/978-1-4939-9748-0_18 · 2020 · External reference
A simple statistical parameter for use in evaluation and validation of high throughput screening assays
10.1177/108705719900400206 · 1999 · External reference
Pathogenicity and virulence of Cryptosporidium
10.1080/21505594.2025.2597642 · 2025 · External reference
Cryptosporidium parvum CpARO marks rhoptry envelope remnants associated with feeder organelle formation
10.1080/21505594.2026.2707806 · 2026 · External reference
Current status and challenges in drug discovery against the globally important zoonotic cryptosporidiosis
10.1186/s44149-021-00002-y · 2021 · External reference
